Molecular Partners AG has appointed Martin Steegmaier as chief scientific officer, effective 1 October, to drive advancement of the company’s pipeline of therapies for cancer. Dr Steegmaier will join from SOTIO Biotech where he was CSO and led the development of oncology programmes. Previously, he was head of research at MorphoSys in 2024. He has also held senior drug discovery roles at Roche and Boehringer Ingelheim.
Copyright 2025 Evernow Publishing Ltd